Compare LTC Properties Inc (LTC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Novavax Inc — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Novavax Inc trades at $12.69 (market cap $1.82B). The key difference: LTC Properties Inc is the larger of the two by market cap, and LTC Properties Inc pays a 5.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Novavax Inc for 59 Days on average.
| LTC | NVAX | |
|---|---|---|
Market Cap | $2.27B | $1.82B |
Volume | 574,171 | 6,198,505 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $12.56 |
52-Week Low | $33.98 | $6.22 |
Typical Hold Time | 88 Days | 59 Days |
Enterprise Value | $3.01B | $1.39B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.46, up 1.55% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 61.72% gross margins and consistent dividend payments of $0.19 monthly. Recent acquisitions totaling $160 million in senior housing properties signal aggressive growth strategy, though cash flow trends show significant investing outflows. Analyst consensus targets $49.67 with 32% buy ratings amid balanced risk-reward outlook.
LTC presents a balanced opportunity with steady income from monthly dividends and demographic tailwinds in senior housing, offset by execution risks from rapid portfolio transformation and rising interest rate sensitivity. The stock trades at reasonable valuations (P/E 15.02) but faces headwinds from its SHOP transition strategy and macroeconomic pressures on REIT valuations.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
